MK-677 vs Ibutamoren — They’re the Same Compound

MK-677 vs Ibutamoren — They're the Same Compound

Here's something that confuses nearly every researcher who orders this peptide for the first time: MK-677 and ibutamoren are not two different compounds you need to choose between. They're the same molecule. The exact same chemical structure. A growth hormone secretagogue that binds to ghrelin receptors in the hypothalamus to stimulate pulsatile GH release without external peptide administration. The naming split happened because pharmaceutical companies assign internal research codes during development (MK-677 was Merck's designation), and sometimes those codes stick even after the generic name (ibutamoren) gets formally assigned by regulatory bodies.

Our team has fielded this question hundreds of times from researchers evaluating peptide protocols. The confusion is understandable. Online suppliers list both names, research papers use both interchangeably, and nobody explains why. This article covers the naming origin, the mechanism that makes this compound distinct from actual growth hormone or GHRP peptides, and why understanding the receptor pathway matters more than memorising both names.

What's the difference between MK-677 and ibutamoren?

There is no difference. MK-677 and ibutamoren are two names for the identical chemical compound (C₂₇H₃₆N₄O₅S). MK-677 was the internal research code assigned by Merck during Phase 2 trials in the 1990s; ibutamoren is the International Nonproprietary Name (INN) assigned later. Both refer to a non-peptide growth hormone secretagogue that mimics ghrelin's action at the GHSR-1a receptor, triggering endogenous GH pulses without suppressing the hypothalamic-pituitary axis the way exogenous GH does.

The reason both names persist is simple: the research code became so widely used in early literature that even after the INN was formalised, suppliers, researchers, and clinical trial registries continued using MK-677. When you see 'MK 677' listed on a certificate of analysis or referenced in a study abstract, it's the same compound as any product labelled 'ibutamoren mesylate'.

The Naming Origin — Research Codes vs Generic Assignments

Pharmaceutical nomenclature operates on two parallel tracks. During early-stage development, compounds get internal alphanumeric codes from the sponsoring company. These codes have no pharmacological meaning but serve as shorthand for researchers tracking multiple candidates through pre-clinical and Phase 1/2 trials. MK-677 was one of several growth hormone secretagogues Merck evaluated in the mid-1990s as a potential oral alternative to injectable recombinant GH. The 'MK' prefix denotes Merck's internal catalogue; the number is sequential.

Once a compound advances far enough to warrant broader regulatory and scientific recognition, the World Health Organisation assigns an International Nonproprietary Name (INN). A standardised generic name that describes the molecule's structure or function. Ibutamoren was assigned as the INN in 1995, derived from the chemical class (secretagogue mimetics ending in '-morelin' or '-moren'). At that point, technically, all formal publications should have switched to 'ibutamoren'. But early Phase 2 data had already been published under MK-677, and that label stuck in research communities.

What this means practically: if you're cross-referencing clinical trials, you'll find studies listed under both names. Sometimes in the same database. ClinicalTrials.gov entries from 1998–2008 predominantly use MK-677; publications after 2010 trend toward ibutamoren. The chemical structure hasn't changed. The pharmacokinetics haven't changed. It's purely a documentation artifact that both names remain in active use across supplier catalogues and research protocols.

Mechanism of Action — How MK-677 (Ibutamoren) Works Differently Than GH or Peptides

MK-677 functions as a selective agonist at the growth hormone secretagogue receptor (GHSR-1a), the same receptor ghrelin. The endogenous 'hunger hormone'. Activates. When ibutamoren binds this receptor in the arcuate nucleus of the hypothalamus, it triggers a downstream signalling cascade that stimulates the anterior pituitary to release growth hormone in pulsatile bursts. This mimics the body's natural GH secretion pattern, which peaks during deep sleep and in response to fasting or exercise.

What sets MK-677 apart from other growth hormone interventions is the preservation of negative feedback loops. Exogenous recombinant GH shuts down the hypothalamic-pituitary axis. When you inject synthetic GH, the body stops making its own because circulating IGF-1 (the downstream product of GH) signals the hypothalamus to halt endogenous production. This suppression can persist for months after stopping exogenous GH. Ibutamoren doesn't trigger this suppression because it works upstream. It stimulates the body's own GH pulse generator rather than replacing it. The pituitary retains control over secretion amplitude and timing.

Compared to GHRP peptides (like GHRP-2 or GHRP-6), MK-677 has two critical advantages: oral bioavailability and extended half-life. GHRP peptides must be injected subcutaneously or intramuscularly because gastric acid degrades the peptide bonds before intestinal absorption. MK-677 is a peptidomimetic. It mimics the peptide's receptor-binding structure but uses a non-peptide scaffold that survives first-pass metabolism. Its half-life ranges from 4 to 6 hours, meaning a single daily oral dose maintains stable receptor activation throughout a 24-hour cycle. GHRP peptides, by contrast, have half-lives under 30 minutes and require multiple daily injections to sustain effect.

MK-677 and Ibutamoren: Practical Comparison

Chemical Structure

C₂₇H₃₆N₄O₅S (peptidomimetic GH secretagogue)

C₂₇H₃₆N₄O₅S (identical molecule)

No structural difference. MK-677 is the research code, ibutamoren is the INN. Both refer to the same compound.

Receptor Target

GHSR-1a (ghrelin receptor) in hypothalamus

Same mechanism. Selective agonism at the growth hormone secretagogue receptor triggers endogenous GH pulses without external peptide.

Half-Life

4–6 hours (oral administration)

Identical pharmacokinetics. Single daily dosing maintains stable receptor activation across a 24-hour cycle.

Bioavailability

~60% oral bioavailability (survives first-pass metabolism)

Same absorption profile. Peptidomimetic structure allows oral dosing, unlike GHRP peptides requiring injection.

IGF-1 Elevation

60–90% increase at 25mg daily (observed in Phase 2 trials)

Same efficacy. Both names describe the compound that elevates circulating IGF-1 via pituitary GH stimulation.

Regulatory Status

Research-grade only (not FDA-approved for human therapeutic use)

Both names carry the same regulatory classification. Available through licensed research suppliers like Real Peptides for investigational purposes only.

Key Takeaways

MK-677 and ibutamoren are the exact same molecule with two names. MK-677 is Merck's internal research code, ibutamoren is the WHO-assigned generic name.

Both names refer to a non-peptide growth hormone secretagogue that binds GHSR-1a receptors to stimulate endogenous GH release without suppressing the hypothalamic-pituitary axis.

The half-life of 4–6 hours allows single daily oral dosing, unlike GHRP peptides requiring multiple injections.

Phase 2 trials documented 60–90% increases in serum IGF-1 at 25mg daily doses, regardless of which name appeared in the protocol title.

Supplier listings may use either name or both. The certificate of analysis matters more than the label, and purity should exceed 98% by HPLC.

Understanding the ghrelin receptor mechanism explains why appetite stimulation is a consistent side effect. GHSR-1a activation increases hunger signalling independent of GH release.

What If: MK-677/Ibutamoren Scenarios

What If a Supplier Lists Both MK-677 and Ibutamoren as Separate Products?

Request the certificate of analysis for both listings and compare the molecular weight, CAS number, and HPLC chromatogram. If the CAS number is 159752-10-0 and the molecular weight is 528.662 g/mol for both, they're the same compound repackaged under different names. Some suppliers list both to capture search traffic from researchers using either term. It's a marketing tactic, not a chemical distinction. The chromatogram peak retention time should be identical if the compound is genuine ibutamoren.

What If Research Literature Refers to 'Ibutamoren Mesylate' Instead of Just Ibutamoren?

Ibutamoren mesylate is the salt form. Ibutamoren base paired with methanesulfonic acid to improve stability and solubility. Most research-grade preparations use the mesylate salt because it's more stable during storage and dissolves more readily in bacteriostatic water or saline for reconstitution. The active component is still ibutamoren; the mesylate counterion doesn't alter the pharmacological mechanism. When calculating dosages, the mesylate salt adds ~15% to the molecular weight, but standard dosing protocols (12.5mg, 25mg) already account for this.

What If You're Cross-Referencing Clinical Trials and Can't Find Data Under One Name?

Search PubMed and ClinicalTrials.gov using both 'MK-677' and 'ibutamoren' as separate queries. Trials conducted before 2005 overwhelmingly used the MK-677 designation; studies after 2010 increasingly adopted ibutamoren. Key trials to reference: the 1999 study published in Journal of Clinical Endocrinology & Metabolism used MK-677 throughout; the 2008 frailty study in Annals of Internal Medicine used ibutamoren. Both examined the same compound at identical doses. The naming shift reflects evolving publication standards, not protocol changes.

The Blunt Truth About MK-677 vs Ibutamoren Confusion

Here's the honest answer: the persistent belief that MK-677 and ibutamoren are different compounds is pure marketing exploitation. Suppliers benefit from listing both names because it doubles their keyword coverage. Researchers searching either term land on their site. Online forums perpetuate the confusion because early discussions used MK-677 exclusively, and those threads still rank high in search results. There's no chemical basis for the distinction. Zero. If a supplier implies one version is 'stronger' or 'purer' than the other, they're either incompetent or dishonest. The molecule is C₂₇H₃₆N₄O₅S regardless of what name appears on the vial label.

The mechanism at the GHSR-1a receptor doesn't change based on nomenclature. The half-life doesn't change. The side effect profile. Appetite stimulation, transient water retention, elevated fasting glucose in some individuals. Remains identical whether the certificate of analysis says MK-677 or ibutamoren mesylate. What matters is the purity (should exceed 98% by HPLC), the reconstitution protocol, and the dosing schedule. The name is irrelevant to the outcome.

Our team has reviewed hundreds of third-party purity reports from suppliers across this space. The pattern is consistent: high-quality ibutamoren comes from synthesis facilities with proper HPLC verification and lyophilisation protocols. Low-quality product shows impurity peaks regardless of whether it's labelled MK-677, ibutamoren, or 'GH secretagogue blend'. Focus on the analytical data, not the marketing label.

The biggest procedural mistake researchers make isn't choosing between names. It's failing to verify reconstitution stability. Once lyophilised ibutamoren is mixed with bacteriostatic water, it remains stable for approximately 30 days when refrigerated at 2–8°C. Temperature excursions above 25°C for more than 48 hours degrade the compound's receptor-binding affinity, and no amount of correct nomenclature fixes that. Store it properly, dose it consistently, and ignore the MK-677 versus ibutamoren debate entirely. It's a distinction without a chemical difference.

If you're evaluating research-grade peptides and secretagogues, the priority is supplier verification. Real Peptides provides batch-specific certificates of analysis with every order, showing exact purity by HPLC and confirming the molecular identity through mass spectrometry. Whether the vial says MK-677 or ibutamoren, the analytical verification is what guarantees you're working with the compound the literature describes.

Frequently Asked Questions

Yes — MK-677 and ibutamoren are two names for the identical chemical compound (C₂₇H₃₆N₄O₅S). MK-677 was Merck’s internal research code during development; ibutamoren is the International Nonproprietary Name assigned by the WHO. Both refer to a non-peptide growth hormone secretagogue that binds ghrelin receptors to stimulate endogenous GH release.

Suppliers list both names to capture search traffic from researchers using either term. Early research literature used MK-677 exclusively, so that designation remains common in online searches. Listing both increases product visibility without changing the underlying compound — it’s a marketing tactic, not a chemical distinction.

MK-677 (ibutamoren) is orally bioavailable and has a 4–6 hour half-life, allowing once-daily dosing. GHRP peptides must be injected because gastric acid degrades peptide bonds, and their half-lives are under 30 minutes, requiring multiple daily administrations. Both stimulate GH release via receptor agonism, but MK-677’s peptidomimetic structure survives first-pass metabolism while true peptides do not.

Phase 2 clinical trials documented 60–90% increases in serum IGF-1 at 25mg daily doses of MK-677 (ibutamoren). This elevation results from sustained pituitary GH secretion triggered by ghrelin receptor activation. The effect is dose-dependent — lower doses (12.5mg) produce smaller but still significant IGF-1 increases.

No — they’re the same molecule, so combining them would simply double the dose of ibutamoren, not add a synergistic effect from two different compounds. If you’re seeing both listed by a supplier, verify the certificate of analysis to confirm they’re identical. Doubling the dose increases side effects (appetite stimulation, water retention) without proportional benefit.

Ibutamoren mesylate is the salt form — ibutamoren base paired with methanesulfonic acid to improve stability and solubility. The mesylate counterion doesn’t change the pharmacological mechanism or receptor binding. Most research-grade preparations use the mesylate salt because it’s more stable during lyophilisation and reconstitution.

No — MK-677 (ibutamoren) stimulates endogenous GH release by activating the ghrelin receptor upstream of the pituitary, so the body’s natural feedback loops remain intact. Exogenous recombinant GH suppresses the hypothalamic-pituitary axis because elevated IGF-1 signals the hypothalamus to stop endogenous production. MK-677 doesn’t trigger this suppression.

Publication naming conventions evolved over time. Trials conducted in the 1990s and early 2000s predominantly used MK-677 because that was the designation in Merck’s original filings. After the WHO assigned the INN ‘ibutamoren’ in 1995, later studies gradually adopted the generic name. Both refer to the same compound — the shift reflects regulatory standardisation, not protocol changes.

The most common side effect is increased appetite, occurring in approximately 40–60% of users, because GHSR-1a activation stimulates hunger signalling independent of GH release. Transient water retention and mild increases in fasting glucose are also documented. These effects are identical whether the product is labelled MK-677 or ibutamoren — the side effect profile is determined by the ghrelin receptor mechanism, not the name.

Research-grade ibutamoren (MK-677) is available through licensed peptide suppliers that provide batch-specific certificates of analysis showing purity by HPLC and molecular identity by mass spectrometry. Purity should exceed 98%. Real Peptides offers verified MK-677 with third-party analytical testing for investigational research purposes.